CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine.

about

CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine.

Item

http://www.wikidata.org/entity/Q48114047

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

CYP1A1 genetic polymorphism is ...... . docetaxel plus capecitabine.

@en

CYP1A1 genetic polymorphism is ...... . docetaxel plus capecitabine.

@nl

type

Item

label

CYP1A1 genetic polymorphism is ...... . docetaxel plus capecitabine.

@en

CYP1A1 genetic polymorphism is ...... . docetaxel plus capecitabine.

@nl

prefLabel

CYP1A1 genetic polymorphism is ...... . docetaxel plus capecitabine.

@en

CYP1A1 genetic polymorphism is ...... . docetaxel plus capecitabine.

@nl

P1476

CYP1A1 genetic polymorphism is ...... . docetaxel plus capecitabine.

@en

P2093

Amy Hobeika

http://www.w3.org/2001/XMLSchema#string

Guoliang Qiao

http://www.w3.org/2001/XMLSchema#string

Michael A Morse

http://www.w3.org/2001/XMLSchema#string

Qingkun Song

http://www.w3.org/2001/XMLSchema#string

William R Gwin

http://www.w3.org/2001/XMLSchema#string

Xiaoli Wang

http://www.w3.org/2001/XMLSchema#string

Xinna Zhou

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives

Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Targeted Therapies for Brain Metastases from Breast Cancer

Weekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines--a phase II multipractice study

Dietary Flavonoids, CYP1A1 Genetic Variants, and the Risk of Colorectal Cancer in a Korean population.

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.

High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials.

Pharmacogenomic biomarkers: validation needed for both the molecular genetic mechanism and clinical effect.

Transformation of alkylating regimen of thiotepa into tepa determines the disease progression through GSTP1 gene polymorphism for metastatic breast cancer patients receiving thiotepa containing salvage chemotherapy.

P2888

s00280-017-3500-9

P304

365-372

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-017-3500-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Herbert Kim Lyerly

Jun Ren

P577

2017-12-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29242966

http://www.w3.org/2001/XMLSchema#string